Headlines about Bruker Corporation (NASDAQ:BRKR) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bruker Corporation earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 47.6043038096436 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern’s scoring:
- Bruker Corporation : SHAREHOLDER ALERT – Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bruker Corporation (BRKR) (4-traders.com)
- Bruker Announces Quarterly Dividend (finance.yahoo.com)
- Bruker Corporation Declares Quarterly Dividend of $0.04 (BRKR) (americanbankingnews.com)
- Q3 2018 Earnings Estimate for Bruker Corporation Issued By Jefferies Group (BRKR) (americanbankingnews.com)
A number of research firms have recently issued reports on BRKR. Zacks Investment Research lowered shares of Bruker Corporation from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Citigroup Inc. upped their target price on shares of Bruker Corporation from $29.00 to $34.00 and gave the stock a “neutral” rating in a report on Friday, November 3rd. Cowen and Company reaffirmed a “hold” rating and set a $29.00 target price on shares of Bruker Corporation in a report on Friday, November 3rd. Bank of America Corporation raised shares of Bruker Corporation from an “underperform” rating to a “neutral” rating and set a $34.00 target price for the company in a report on Friday, November 3rd. Finally, J P Morgan Chase & Co raised shares of Bruker Corporation from an “underweight” rating to a “neutral” rating and set a $28.00 target price for the company in a report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $29.64.
Bruker Corporation (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.02. Bruker Corporation had a net margin of 8.85% and a return on equity of 25.83%. The firm had revenue of $435.60 million for the quarter, compared to analysts’ expectations of $415.45 million. During the same quarter in the previous year, the company posted $0.32 EPS. The company’s revenue was up 10.6% compared to the same quarter last year. analysts expect that Bruker Corporation will post 1.19 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 22nd. Shareholders of record on Monday, December 4th will be given a $0.04 dividend. The ex-dividend date is Friday, December 1st. This represents a $0.16 dividend on an annualized basis and a yield of 0.49%. Bruker Corporation’s payout ratio is currently 17.02%.
In other Bruker Corporation news, VP Mark Munch sold 21,061 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the transaction, the vice president now owns 60,524 shares of the company’s stock, valued at $1,813,904.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 35.20% of the company’s stock.
About Bruker Corporation
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.